Synergistic interaction between methotrexate and a superoxide dismutase mimetic: Pharmacologic and potential clinical significance
Open Access
- 30 November 2005
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 52 (12), 3755-3760
- https://doi.org/10.1002/art.21480
Abstract
Objective To investigate the effects of combination therapy with M40403 and methotrexate (MTX) on collagen-induced arthritis (CIA) in rats. Methods CIA was elicited in Lewis rats that had been assigned to different experimental groups, and the rats were treated daily, starting at the onset of arthritis (day 26), with M40403 2 mg/kg intraperitoneally, MTX 0.15 mg/kg orally, or combination therapy (M40403 2 mg/kg plus MTX 0.015 mg/kg). Results The histopathologic features of CIA in type II collagen–challenged rats included erosion of the articular cartilage and bone resorption. Treatment of rats with MTX 0.15 mg/kg orally delayed the development of clinical signs (days 26–35) and improved histologic status in the knee and paw, as clearly demonstrated by a significant reduction in erosion of the articular cartilage at the joint margins and subchondral bone resorption. Furthermore, radiographic evidence of protection against bone resorption and soft tissue swelling was apparent in the tibiotarsal joints of rats treated with MTX 0.15 mg/kg daily. Furthermore, combination therapy with M40403 2 mg/kg plus MTX 0.015 mg/kg exerted significant protection against the development of arthritis, similar to that observed with MTX alone at a dose of 0.15 mg/kg. In contrast, no significant protection was observed in animals treated with M40403 2 mg/kg alone or with MTX 0.015 mg/kg alone. Conclusion This study provides the first evidence that M40403, a potent superoxide dismutase mimetic, exerts a significant synergistic effect with MTX in rats with CIA.Keywords
This publication has 17 references indexed in Scilit:
- Effects of combination M40403 and dexamethasone therapy on joint disease in a rat model of collagen‐induced arthritisArthritis & Rheumatism, 2005
- Oxidative stress contributes to methotrexate-induced small intestinal toxicity in ratsScandinavian Journal of Gastroenterology, 2004
- Safty, efficacy, and mortality in a long‐term cohort of patients with rheumatoid arthritis taking methotrexate: Folloup after a mean of 13.3 yearsArthritis & Rheumatism, 1997
- Biologic agents for treating rheumatoid arthritis. Concepts and progressArthritis & Rheumatism, 1997
- THE EFFECT OF LIPOSOMALLY CONJUGATED METHOTREXATE UPON MEDIATOR RELEASE FROM HUMAN PERIPHERAL BLOOD MONOCYTESRheumatology, 1995
- Adhesion molecules in the pathogenesis of rheumatoid arthritisCurrent Opinion in Rheumatology, 1994
- The comparative efficacy and toxicity of second‐line drugs in rheumatoid arthritis results of two metaanalysesArthritis & Rheumatism, 1990
- Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long‐term treatmentArthritis & Rheumatism, 1989
- Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A Controlled Clinical TrialArthritis & Rheumatism, 1985
- The protein binding of methotrexate by the serum of normal subjectsEuropean Journal of Clinical Pharmacology, 1979